PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.48%
Negative revenue growth while CRON.TO stands at 30.63%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-18.23%
Negative gross profit growth while CRON.TO is at 95.38%. Joel Greenblatt would examine cost competitiveness or demand decline.
-61.11%
Negative EBIT growth while CRON.TO is at 9.51%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-61.11%
Negative operating income growth while CRON.TO is at 6.32%. Joel Greenblatt would press for urgent turnaround measures.
-205.02%
Negative net income growth while CRON.TO stands at 36.57%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-181.58%
Negative EPS growth while CRON.TO is at 40.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-181.58%
Negative diluted EPS growth while CRON.TO is at 40.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
9.00%
Share count expansion well above CRON.TO's 0.20%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
9.00%
Diluted share count expanding well above CRON.TO's 1.06%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-102.79%
Negative OCF growth while CRON.TO is at 21.68%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
65.09%
FCF growth above 1.5x CRON.TO's 19.68%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
998.76%
5Y revenue/share CAGR under 50% of CRON.TO's 3632.50%. Michael Burry would suspect a significant competitive gap or product weakness.
70.17%
3Y revenue/share CAGR under 50% of CRON.TO's 234.15%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
99.10%
OCF/share CAGR of 99.10% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
-100.92%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
99.69%
Positive 3Y OCF/share CAGR while CRON.TO is negative. John Neff might see a big short-term edge in operational efficiency.
-3992.18%
Negative 10Y net income/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-2769.45%
Negative 5Y net income/share CAGR while CRON.TO is 7841.86%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-171.89%
Negative 3Y CAGR while CRON.TO is 765.33%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
3001.42%
Equity/share CAGR of 3001.42% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
191.30%
Below 50% of CRON.TO's 979.73%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-26.97%
Negative 3Y equity/share growth while CRON.TO is at 304.83%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.91%
Firm’s AR is declining while CRON.TO shows 32.66%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-0.89%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
1.70%
Positive asset growth while CRON.TO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-24.79%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
72.83%
Debt growth far above CRON.TO's 36.65%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-42.29%
Our R&D shrinks while CRON.TO invests at 24.50%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
39.21%
SG&A growth well above CRON.TO's 20.54%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.